The chemical class of KLHL13 Activators encompasses a range of compounds that indirectly influence the activity of KLHL13, a member of the BTB-Kelch superfamily known for its role in protein ubiquitination and degradation. This class does not consist of chemicals that directly bind or activate KLHL13. Instead, it includes compounds that modulate various cellular pathways and processes, which in turn can impact KLHL13's functional role in the cell. Key members of this class are proteasome inhibitors such as MG132, Epoxomicin, Lactacystin, and Bortezomib. These compounds inhibit the proteasome, leading to an accumulation of ubiquitinated proteins. This increase in ubiquitinated proteins influence the ubiquitin-proteasome system where KLHL13 operates, thereby indirectly activating its activity. By altering the dynamics of protein degradation and ubiquitination, these inhibitors provide a window into understanding how changes in these processes can impact proteins like KLHL13.
In addition to proteasome inhibitors, this class includes compounds that affect various signaling pathways, intersecting with the regulatory network of KLHL13. Wnt Agonist 1, BIO, and LiCl, for instance, are involved in modulating the Wnt signaling pathway. Since Wnt signaling plays a crucial role in numerous cellular processes, its modulation can indirectly affect the functional landscape where KLHL13 is active. Similarly, GSK-3 inhibitors like SB216763, and kinase inhibitors such as PD98059 (a MEK inhibitor) and SP600125 (a JNK inhibitor), impact signaling pathways that could have downstream effects on KLHL13. Forskolin, known for increasing intracellular cAMP levels, affects a wide array of signaling pathways, thereby influencing KLHL13's activity. Lastly, Rapamycin, an mTOR inhibitor, by altering cellular growth and metabolic pathways, also contributes to the indirect modulation of KLHL13. Collectively, these compounds, through their diverse mechanisms of action, underscore the complex interplay of signaling pathways and protein regulation in which KLHL13 is a key participant, highlighting the intricate nature of cellular regulation and the indirect effects on specific proteins such as KLHL13.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wnt Agonist | 853220-52-7 | sc-222416 sc-222416A | 5 mg 25 mg | $157.00 $609.00 | 23 | |
Activates Wnt signaling, a pathway that could intersect with KLHL13's function in cellular processes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Influences the Wnt/β-catenin pathway, potentially affecting cellular processes where KLHL13 is involved. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, leading to increased cAMP, which can affect multiple signaling pathways related to KLHL | ||||||